Industry news that matters to you.  Learn more

Cytokine Antibody Array Assays Developed by RayBiotech, Inc. Used to Identify Key Cancer Cell Chemoresistance Pathway

RayBiotech, Inc. announced today that several antibody-based biomarker screening assays developed by the company were utilized to identify a critical pathway involved in chemotherapeutic resistance acquired by melanoma cancer cells.

Specifically, the RayBio┬« G-Series 4000 and the RayBio┬« L-Series 507 cytokine antibody arrays allowed the characterization of a specific pathway associated with the cancer cells’ ability to develop resistance to chemotherapeutic agents. Utilizing RayBiotech’s antibody arrays, the authors discerned that the microenvironment of a melanoma tumor plays a crucial role in modulating resistance to certain cancer drugs. In addition, the arrays helped to identify individual factors acting upon cancer cells that are both necessary and sufficient to drive chemoresistance. These studies revealed unique biochemical and molecular targets for possible therapeutic intervention for the treatment and management of melanoma. The seminal research was published in Nature (Nature. 2012 Jul 26; 487:500-4).

Commenting on the research, RayBiotech’s President and Chief Operating Officer Rani Huang stated, “The findings of this research have comprehensively outlined a novel mechanism behind the acquisition of chemoresistance by one of the deadliest forms of cancer. We are pleased that RayBiotech’s antibody arrays played important roles in chemoresistance pathway characterization. This is a perfect example of how our high-content screening tools can facilitate potential drug target identification.”

Study: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Source: Market Wire

RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration

RayBiotech, Inc. and the combined genotyping core facility for Oslo University Hospital and the University of Oslo, located at the Institute for Cancer Research, announced the execution of an agreement to collaborate for the implementation of antibody-based sample analysis services. Under the terms of the agreement, the combined core facility will provide a comprehensive service utilizing RayBiotech’s proprietary antibody arrays for the high-throughput detection and analysis of protein biomarkers in biological samples. The service program will target academic and industrial research clients having a need for fully quantifiable biomarker analysis.

RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program

RayBiotech, Inc. announced recently that it has formally launched a partnering program for select diagnostic core facilities at academic and government research institutes in the United States and Canada.

RayBiotech Renews BIomarker Discovery Grant Program for 2011

RayBiotech, Inc., The Protein Array Pioneer Company, announced today it will renew its Biomarker Discovery Pilot Grant program for 2011. RayBiotech will accept applications for pilot grants beginning in early 2011. Winning applicants will be eligible for restricted grants of $5,000 to $20,000 worth of RayBiotech products and/or services for conducting biomarker research.